逍遥散治疗非酒精性脂肪性肝病作用机制研究进展

张馨日; 初昀杭; 陈星宇; 冷炎

文章摘要

张馨日,初昀杭,陈星宇,冷炎.逍遥散治疗非酒精性脂肪性肝病作用机制研究进展[J].,2025,34(24):54-58

逍遥散治疗非酒精性脂肪性肝病作用机制研究进展

Research Progress on the Mechanism of Xiaoyao Pill in the Treatment of Nonalcoholic Fatty Liver Disease

投稿时间：2025-03-13

DOI：

中文关键词: 非酒精性脂肪性肝病逍遥散作用机制研究进展

英文关键词: Nonalcoholic Fatty Liver Disease Xiaoyao Pill Mechanism of Action Research Progress

基金项目:吉林省科学技术厅(20240304068SF)。

作者	单位
张馨日	长春中医药大学，吉林长春 130117
初昀杭	长春中医药大学，吉林长春 130117
陈星宇	长春中医药大学附属医院，吉林长春 130021
冷炎	长春中医药大学附属医院，吉林长春 130021

摘要点击次数: 153

全文下载次数: 0

中文摘要:

非酒精性脂肪性肝病，为我国第一大慢性肝病。近年来，诸多研究表明中医药在整体观念与辨证论治思维指导下运用逍遥散治疗非酒精性脂肪性肝病具有独特优势，临床效果显著，但对其作用机制的探讨尚未完备。本研究通过检索相关文献，对逍遥散治疗非酒精性脂肪性肝病的作用机制作一综述，以期为临床运用逍遥散治疗非酒精性脂肪性肝病提供理论依据。研究结果显示，在药理作用方面，逍遥散中的主要活性成分可以通过相关靶点／通路改善非酒精性脂肪性肝病。在作用机制方面，逍遥散能够通过促进脂肪酸 β氧化以调节脂质代谢、减轻胰岛素抵抗、减少炎症因子的释放以抑制炎症反应、调节肠道菌群以修复肠黏膜屏障及维持铁稳态，进而改善非酒精性脂肪性肝病。相关疗效分析证实，逍遥散可降低血清丙氨酸氨基转移酶 ( alanine aminotransferase , ALT) 、天门冬氨酸氨基转移酶 ( aspartate aminotransferase ,AST) 、γ- 谷氨酰转肽酶 ( γ- glutamyl transpeptidase , GGT) 及总胆固醇 ( total cholesterol , TC) 、甘油三酯 ( triglyceride ,TG) 水平，同时减轻肝细胞脂肪变性程度。

英文摘要:

Nonalcoholic fatty liver disease is the largest chronic liver disease in China. In recent years , many studies have shown that under the guidance of the overall concept and the thinking of syndrome differentiation and treatment , the application of Xiaoyao Pill in the treatment of nonalcoholic fatty liver disease has unique advantages and significant clinical effects , but the discussion on its mechanism of action is not yet complete . This study reviewed the mechanism of Xiaoyao Pill in the treatment of nonalcoholic fatty liver disease by searching the relevant literature , in order to provide a theoretical basis for the clinical application of Xiaoyao Pill in the treat- ment of nonalcoholic fatty liver disease . The results showed that in terms of pharmacological effects , the main active ingredients in Xiaoyao Pill can improve nonalcoholic fatty liver disease through related targets / pathways . In terms of mechanism of action , Xiaoyao Pill can improve nonalcoholic fatty liver disease by promoting fatty acid βoxidation to regulate lipid metabolism , reducing insulin resistance , reducing the release of inflammatory factors to inhibit inflammatory response , regulating intestinal flora to repair intestinal mucosal barrier and maintain iron homeostasis . The relevant efficacy analysis confirmed that Xiaoyao Pill could reduce the levels of serum alanine aminotransferase (ALT) , aspartate aminotransferase (AST) , γ - glutamyl transpeptidase (GGT) , total cholesterol (TC) , triglyceride (TG) and hepatocyte steatosis .

查看全文查看/发表评论下载PDF阅读器